Androgen receptor (AR) is expressed in all stages of prostate cancer progression, including in castration-resistant tumors. Eliminating AR function continues to represent a focus of therapeutic investigation, but AR regulatory mechanisms remain poorly understood. To systematically characterize mechanisms involving microRNAs
Treatment of advanced prostate cancer (PCa) relies on pharmacological or surgical androgen deprivation. However, it is only temporarily efficient. After a few months or years, the tumor relapses despite the absence of androgenic stimulation: a state referred to as hormone-refractory
Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth
Zhu YP, et al.
Testing, 6(16), 14488-14488 (2015)
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
Martin AM, et al.
Prostate Cancer and Prostatic Diseases, 18(4), 325-325 (2015)
Androgen receptor antagonist bicalutamide induces autophagy and apoptosis via ULK2 upregulation in human bladder cancer cells
Hao K, et al.
International Journal of Clinical and Experimental Pathology, 10(7), 7603-7615 (2017)
We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.
